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ABSTRACT
 Bannayan-Riley-Ruvalcaba syndrome (BRRS) 
is a rare autosomal, dominantly-inherited, hamar-
toma syndrome with distinct phenotypic features. 
Mutations in the PTEN gene have been identifi ed in 
PTEN hamartoma tumor syndromes. Our aim was 
to determine the correlation of phenotype-genotype 
relationships in a BRRS case. We have evaluated a 
PTEN mutation in a patient with vascular anoma-
lies and the phenotypic fi ndings of BRRS. We de-
scribed an 8-year-old girl with the clinical features 
of BRRS, specifi cally with vascular anomalies. The 
mutation in the PTEN gene was identifi ed by DNA 
sequencing. In our patient, we defi ned a de novo 
nonsense R335X (c.1003 C>T) mutation in exon 
8, which results in a premature termination codon. 
Due to vascular anomalies and hemangioma, the pa-
tient’s left leg was amputated 1 year after the hem-
angioma diagnosis. Bannayan - Riley - Ruvalcaba 
syndrome patients with macrocephaly and vascular 
anomalies should be considered for PTEN mutation 
analysis and special medical care.
 Keywords:      Bannayan - Riley - Ruvalcaba
Syndrome (BRRS); Hemangioma; Macrocephaly; 
PTEN gene; Vascular anomalies.
 INTRODUCTION
 Bannayan-Riley-Ruvalcaba Syndrome (BRRS; 
Online Mendelian Inheritance in Man data base, 
OMIM 153480) is a rare autosomal, dominantly-
inherited, congenital disorder characterized by 
macrocephaly, lipomatosis, hemangiomatosis, ham-
artomatous growths, central nervous system ab-
normalities, genital lentiginosis, intestinal polypo-
sis, vascular malformations, and, less commonly, 
mental retardation [1-3]. Common facial presen-
tations in BRRS patients include frontal bossing, 
down-slanting palpebral fi ssures, strabismus hyper-
telorism, a depressed nasal bridge, long philtrum, 
epicanthus inversus, a thin upper lip, a broad mouth 
and relative micrognathia [4,5]. Hypothonia, de-
layed psychomotor development, and seizures are 
also observed in at least half of BRRS patients [2]. 
Additionally, ocular abnormalities, lipid storage 
myopathy, and skeletal system abnormalities such 
as pectus excavatum, joint hyperextensibility and 
scoliosis are common manifestations of the syn-
drome [5]. Bannayan-Riley-Ruvalcaba syndrome 
and Cowden syndrome (CS; MIM 158350) are two 
hamartoma syndromes that sometimes show clini-
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cal overlap. Thus, at least a subset of BRRS and 
CS may be allelic. Approximately 60% of patients 
with BRRS have an identifi able germline mutation 
in PTEN (OMIM 601728), which is a tumor sup-
pressor gene located on chromosome 10 (10q23) 
[6,7]. The PTEN gene has nine exons that encode 
a protein of 403 amino acids, and is also known as 
MMAC1 (mutated in multiple advanced cancers) or 
TEP1 (TGF-regulated and epithelial cell-enriched 
phosphatase) [8]. It has been suggested that syn-
dromes characterized by the presence of germline 
PTEN mutations might be referred to as PTEN ham-
artoma tumor syndromes (PHTS).
 In the present study, we have performed PTEN 
mutation analysis in a patient with BRRS. We found 
a de novo nonsense R335X (c.1003C>T) mutation 
that is rarely reported in the literature for BRRS 
patients. Furthermore, we attempted to discuss the 
clinical features of BRRS which should prompt 
clinicians to test for a PTEN mutation.
 MATERIALS AND METHODS
 Clinical Report. The proband was an 8-year-
old female, referred to the Neurogenetic Division, 
University of São Paulo-Clinics Hospital, Ribeirao 
Preto, São Paulo, Brazil, because of recurrent facial 
palsy. She was the second child of healthy and non 
onsanguineous parents. Further family history was 
unremarkable. She was born by vaginal delivery 
at term; her birth weight, length, and occipitofron-
tal circumference (OFC) were not recorded at that 
time. Her growth parameters were normal during 
childhood. At 2 years of age, she developed recur-
rent attacks of facial palsy with full recovery days 
after the episode; there were no other similar cases 
in her family. Her medical history included one epi-
sode of seizures at 3 years of age, but she did not use 
anticonvulsants. At 7 years of age, she developed 
gait problems because of pain in her left leg and was 
evaluated by an orthopedic surgeon who diagnosed 
hemangiomas. The hemangioma was excised. After 
histopathological examination, the lesion was diag-
nosed as an angiolipoma. However, she had another 
hemangioma in the same leg several months later. 
At that time her parents noticed that her leg became 
thinner. New hemangiomas appeared in her right 
leg, but the parents decided not to operate until they 
had a defi nite diagnosis. Her teachers noticed learn-
ing disabilities in school. At the age of 8, her weight 
and height were in the 50th percentile and her OFC 
was greater than the 97th percentile for her age. 
Her parents’ OFC were in the normal range. When 
she was 10, her left leg was amputated because of 
the hemangioma. On phenotypic inspection, a mild 
facial dysmorphism consisting of a high forehead, 
a triangular face, pointed chin, down-slanting pal-
pebral fi ssures, and a high-arched palate were ob-
served. Several verrucae vulgares on her arms and 
hands and small café-au-lait spots on her arms and 
trunk were identifi ed.
 Neurological examination identifi ed a mildly 
asymmetric face, normal eye movements, brisk 
osteotendinous refl exes, and no signs of cerebellar 
ataxia. Interestingly, the patient had facial palsy. 
The weakness in her left leg included a moderate 
degree of muscle atrophy and aqueous retraction. 
Her biochemical and serological tests (including 
thyroid function and karyotype) were all normal. 
Electroencephalogram (EEG) monitoring recorded 
as normal. Electromyography (EMG) revealed the 
presence of myopathic potential units, but nerve 
conduction velocities were normal. Abdominal 
ultrasound monitoring recorded as normal. 
Magnetic resonance imaging (MRI) of the brain 
showed a small cavitation on the atrium of left lateral 
ventricle compatible with increased perivascular 
space. An MRI  of the lower limbs showed 
normal fi ndings in left leg; her right leg displayed 
the presence of arteriovenous malformation 
of the right buttock thorough the right lower 
limbs and severe muscle atrophy. Because of the 
combination of macrocephaly, angiomyolipomas, 
and myopathy, we hypothesized that she might 
have Bannayan-Zonana syndrome, and performed 
a thyroid ultrasound and colonoscopy. The 
thyroid ultrasound showed no abnormal fi ndings; 
colonoscopy showed a few polyps in the sigmoid 
colon. The results of biopsy on the polyps were 
compatible with hamartomatous type lesions. In 
our patient, the existence of hemangiomas, severe 
vascular malformation leading to amputation of 
an extremity, macrocephaly, dermatologic and 
neurologic fi ndings, and facial dysmorphisms in 
childhood supported a diagnosis of BRRS and an 
evaluation of PTEN mutation analysis. After we 
obtained written informed consent from her parents 
(Ethical Committee for Medical Research document 
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number 12219/2004), we carried out a direct DNA 
sequencing of the whole PTEN gene exons.
 Characterization of the PTEN Mutation. 
We extracted genomic DNA from peripheral blood 
leukocytes by means of a commercial kit (QIAamp 
51104; Qiagen, Hilden, Germany). We then 
amplifi ed genomic DNA using primers fl anking 
the exons of PTEN. Primer sequences and their Tm 
values are given in Table 1. Reaction conditions 
were as follows: after initial denaturation at 98C 
for 1 min., three steps were repeated for 35 cycles 
(denaturation for 8 seconds at 98C, annealing for 
8 seconds at 60C and extension for 15 seconds 
at 72C). The reaction was fi nished with a fi nal 
extension for 1 min. at 72C. The polymerase chain 
reaction (PCR) products were directly sequenced 
by a sequencing service company, Iontek (Istanbul, 
Turkey), to detect mutation. We used the Mutation 
Surveyor software package (v 3.10, SoftGenetics, 
LLC, State College, PA, USA) for mutation 
screening.
 RESULTS
 A nonsense R335X (c.1003C>T) mutation was 
identifi ed in exon 8 that resulted in a premature 
termination codon (Figure 1). The mutation was 
confi rmed with the second sequencing reaction and 
another round of mutation screening procedures. 
Sequencing analysis of PTEN exon 8 in the patient’s 
parents failed to reveal any alteration.
 DISCUSSION
 The PTEN mutation is related to hamartoma 
syndromes, displaying partial clinical overlap. The 
determination of germline mutations in PHTS can 
allow the identifi cation of new genotype-phenotype 
correlations, particularly in BRRS. However, it was 
reported that males are more frequently affected 
than females but our female patient was in the group 
of lower penetrance group [9]. We have identifi ed 
a de novo mutation, R335X, in the PTEN coding 
sequence in a child with the phenotypic fi ndings of 
BRRS. Although this truncating PTEN mutation is 
common in CS, the R335X mutation is rarely re-
ported in BRRS [2]. The R335X mutation at nucleo-
tide 1003 (C>T) in exon 8 results in a truncated pro-
tein lacking the C-terminal portion that is needed 
for phosphatase function [2]. Destabilization of the 
predicted secondary structure by point mutations on 
the C-terminal has been shown to result in haploin-
suffi ciency and to affect phosphatase function [10]. 
Since we did not analyze the DNA of affected tis-
sues, we speculate that a single PTEN hit resulting 
in PTEN haploinsuffi ciency may be causative of the 
patient’s clinical features, such as macrocephaly, 
verrucae vulgares, café-au-lait spots, seizures and 
hemangiomas.
 Çelebi et al. [2] described for the fi rst time a 
family with two female members fulfi lling the 
criteria for CS and two male members with the 
phenotypic fi ndings of BRRS associated with 
Table 1. The PTEN primers [forward (F) and reverse (R)] used in this study.
Primer Sequence (5’>3’) Tm (C) Product Size (bp)
PTEN exon 1ALTF
PTEN exon1R
ATT TCC ATC CTG CAG AAG AAG
ATC CGT CTA CTC CCA CGT TCT
58.40
60.00 231
PTEN exon2F
PTEN exon2R
CAT TGA CCA CCT TTT ATT ACT CCA
CTT TTC TAA ATG AAA ACA CAA CAT GAA
69.33
59.88 290
PTEN exon3F
PTEN exon3R
CCA TAG AAG GGG TAT TTG TTG G
AAC TCT ACC TCA CTC TAA CAA GCA GA
59.60
59.25 301
PTEN exon4F
PTEN exon4R
TGT CAC ATT ATA AAG ATT CAG GCA AT
TCT CAC TCG ATA ATC TGG ATG ACT
60.15
59.26 246
PTEN exon5F
PTEN exon5R
CCT GTT AAG TTT GTA TGC AAC ATT TC
TCT CAG ATC CAG GAA GAG GAA A
60.21
60.32 385
PTEN exon6F
PTEN exon6R
GGC TAC GAC CCA GTT ACC ATA
GCT TCA GAA ATA TAG TCT CCT GCA T
59.00
59.38 365
PTEN exon7F
PTEN exon7R
TGA GAT CAA GAT TGC AGA TAC AGA
ACC AAT GCC AGA GTA AGC AAA
59.00
59.76 438
PTEN exon8F
PTEN exon8R
AAT AGT CTT TGT GTT TAC CTT TAT TCA G
TCA AGC AAG TTC TTC ATC AGC
57.05
58.24 488
PTEN exon9F
PTEN exon9R
AAG ATC ATG TTT GTT ACA GTG CTT
CTG GTA ATC TGA CAC AAT GTC CT
57.10
58.12 434
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PTEN R335X mutation. Marsh et al. [11] reported 
a CS patient with the PTEN gene R335X mutation 
with malignancy. Parisi et al. [10] reviewed their 
experience in three families with BRRS and PTEN 
mutations. Similarly, we encountered common 
phenotypic features identifi ed in approximately 
one-third of their patients, who had downward-
slanting palpebral fi ssures, high-arched palates, 
macrocephaly, frontal bossing, vascular 
malformations, café-au-lait macules, seizures, and 
some degree of learning impairment [10]. Fifty-six 
to 70% of BRRS patients also exhibited high-arched 
palates [10].
 Zhou et al. [12] intended to defi ne whether 
other syndromes of overgrowth and hamartomas 
are part of PHTS. They also studied six unrelated 
individuals who had minimal features of lipomas, 
hamartomas, and overgrowth but did not meet the 
diagnostic criteria of CS and BRRS; they subjected 
these patients to PTEN mutation analysis. In their 
study, a germline PTEN R335X mutation and a 
second “hit” germline mosaic R130X mutation, were 
detected in affected tissues of a boy with clinical 
features of marked hemihypertrophy, macrocephaly, 
epidermoid nevi, and lipomas. The patient had been 
diagnosed with an undefi ned Proteus-like syndrome. 
The patient had arteriovenous malformations in all 
tissues, including muscle, nerve, and bone. The 
malformations progressively worsened, and after a 
series of embolizations, a right hip amputation was 
performed. Since he did not have any gastrointestinal 
symptoms, this patient did not meet the criteria for a 
diagnosis of CS or BRRS [12].
 Another small series of Proteus syndrome 
patients was examined for PTEN mutations [13-15]. 
Interestingly, R335X was found in two of fi ve Proteus-
like individuals and the same mutation has also 
been found in CS and BRRS patients [15]. Vascular 
abnormalities, arteriovenous malformations, 
vascular hamartomas, or hemangiomas, have been 
reported in some BRRS and CS patients [16-18]. 
These vascular anomalies are typically multifactorial 
intramuscular combinations of fast-fl ow channels 
and ectopic fat in patients with PTEN mutations 
[19]. Nevertheless, monitoring for vascular 
anomalies is not a standard diagnostic procedure for 
BRRS patients [19]. Erkek et al. [1] reported tender 
and painful arteriovenous hemangiomas that were 
misdiagnosed as angiolipomas in their patients. In 
this report, the patient’s most striking features were 
the limitation of vascular hamartomas, myopathy, 
axonal neuropathy and enostosis to the right lower 
extremity.
 Tan et al. [19] identifi ed vascular anomalies in 
54% of their patients positively identifi ed as having 
a PTEN mutation, although none of them had 
 Figure 1. Electropherograms of a normal and patient’s DNAs showing the heterozygous R335X mutation 
(Ensembl Transcript ID: ENST00000371953).
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hemangiomas or other pure vascular tumors. They 
found the R335X mutations in two male patients, 
one with vascular anomalies and one without. 
They concluded in this research that macrocephalic 
patients with fast-fl ow vascular anomalies or 
multiple intracranial developmental venous 
anomalies should be tested for PTEN mutation [19]. 
Although a few cases have been reported with the 
association of CS, hemangiomas and arteriovenous 
malformations are reported features of BRRS 
[20]. Electromyography may refl ect the myopathic 
process [21].
 We showed the presence of myopathic potential 
units in our patient. Bannayan-Riley-Ruvalcaba 
syndrome is also associated with muscular 
abnormalities [1]. Our patient had weakness in her 
left leg with moderate degree of muscle atrophy 
and aqueous aquileus retraction. Hamartomatous 
polyposis occurs in 35-45% of BRRS cases, mainly 
in the colon and rectum [5,8,22]. The results of our 
patient’s colonoscopy showed a few polyps in the 
sigmoid colon; a biopsy showed that the polyps 
were compatible with a hamartomatous type. Timely 
identifi cation of PTEN mutations, regardless of 
clinical presentation, would redefi ne a diagnosis. 
Severe arteriovenous malformations/ hemangiomas 
may be a particular presentation of BRRS patients 
carrying the R335X mutation and can be a debilitating 
feature of the disease.
 We aimed to evaluate genetic features of 
BRRS, demonstrating clinical correlations in a 
demonstrated case. Our study has contributed to 
the knowledge of vascular anomalies in patients 
with a PTEN mutation. This case report reminds the 
clinicians to consider a PTEN gene mutation testing 
for diagnosis of patients with vascular anomalies 
and other clinical features of CS and BRRS.
 Declaration of Interest. The authors report 
no confl icts of interest. The authors alone are 
responsible for the content and writing of this 
article.
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